

## **BioSpecifics Technologies Corp. to Present at SEVEN, Noble Financial Capital Markets' Seventh Annual Equity Conference**

LYNBROOK, NY – May 11, 2011 - BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at SEVEN, Noble Financial Capital Markets' Seventh Annual Equity Conference on Tuesday, May 17th at 9:30am EDT at the Hard Rock Hotel in Hollywood, Florida.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at [www.biospecifics.com](http://www.biospecifics.com), or you may use the link: <http://noble.mediasite.com/mediasite/Viewer/?peid=546a50205ba1497a9a06f4122a1b3f071d>.

### **About BioSpecifics Technologies Corp.**

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX<sup>®</sup> in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX<sup>®</sup> in Europe and has announced European regulatory approval and the first commercial sale in the United Kingdom. Asahi Kasei Pharma Corporation is responsible for marketing XIAFLEX<sup>®</sup> in Japan. More information about BioSpecifics Technologies Corp. may be found on its website at [www.biospecifics.com](http://www.biospecifics.com).

### **Contact:**

BioSpecifics Technologies Corp.  
Thomas L. Wegman, President  
(516) 593-7000  
[thomas\\_wegman@biospecifics.com](mailto:thomas_wegman@biospecifics.com)